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Introduction
Human  bone  marrow  mesenchymal  stem  cells 
(BMMSCs)  have  been  identified  as  a  population  of 
postnatal stem cells with the potential to self-renew and 
differentiate into osteoblasts, chondrocytes, adipocytes, 
and  neural  cells  [1-5].  BMMSCs  also  exhibit  immuno-
modulatory and regulatory effects on T and B lympho-
cytes, dendritic cells, and natural killer cells, indicating 
an attractive feature for cell therapy [6-11]. In addition, 
culture  expanded  BMMSCs  may  fail  to  express  MHC-
class  II  antigens  on  their  surfaces,  therefore  allogenic 
BMMSCs have been used in treating a variety of diseases 
such as acute graft-versus-host-disease (GVHD) [12-14], 
ame  lio  rat  ing Hematopoietic Stem Cell engraftment [15, 
16],  and  systemic  lupus  erythematosus  (SLE)  [17]. 
Recently,  mesenchymal  stem  cells  derived  from  other 
tissues  have  also  been  found  to  possess  immuno-
modulatory functions [18-20] which offer opportunities 
to find more effective and feasible mesenchymal stem cell 
sources for cell therapies.
Stem  cells  from  human  exfoliated  deciduous  teeth 
(SHED)  have  been  isolated  from  naturally  exfoliated 
deciduous  teeth  with  the  capacity  to  differentiate  into 
osteogenic and odontogenic cells, adipocytes, and neural 
cells [21]. As neural crest cell-associated postnatal stem 
cells,  SHED  express  a  variety  of  neural  cell  markers 
including  nestin,  beta  III  tubulin,  GAD,  NeuN,  GFAP, 
NFM,  and  CNPase  [21].  Also,  SHED  are  able  to  form 
bone when transplanted in vivo [22] and offer obvious 
bone  regeneration  for  repairing  calvarial  defects  in  a 
mouse model [23]. It is unknown whether SHED possess 
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medium, provided the original work is properly cited.immunomodulatory  function  as  seen  in  BMMSCs.  In 
this  study,  we  compare  immuno-regulatory  properties 
between SHED and BMMSCs and utilize SHED trans-
plantation to treat SLE-like diseases in a murine model.
Materials and methods
Mice
C57BL/6J  and  C3MRL-Faslpr/J  (MRL/lpr)  mice  (female, 
six- to seven-week-old) were purchased from the Jackson 
Laboratory (Bar Harbor, ME, USA). Beige nude/nude Xid 
(III)  mice  (female,  8-  to  12-week-old)  were  purchased 
from Harlan (Indianapolis, IN, USA). All animal experi-
ments were performed under an institutionally approved 
protocol  for  the  use  of  animal  research  (University  of 
Southern California protocol #10874 and #10941).
Human tooth, bone marrow and peripheral blood samples
Human exfoliated deciduous incisors were obtained as 
discarded biological samples from children (six- to eight-
year-old)  at  the  Dental  Clinic  of  the  University  of 
Southern California following the approved Institutional 
Review Board guidelines. Healthy bone marrow aspirates 
from iliac bone and peripheral blood mononuclear cells 
(PBMNCs)  of  healthy  volunteers  were  purchased  from 
AllCells (Berkeley, CA, USA).
Isolation and culture of SHED and BMMSCs
Mononuclear cells isolated from the remnant dental pulp 
tissue of the deciduous incisors were cultured as reported 
previously  [21,  24].  BMMSCs  culture  was  described 
previously [25]. The detailed protocols were described in 
Additional file 1.
Cell surface markers analysis
The procedure for single colored flow cytometry (FCM) 
was  performed  as  described  previously  [26,  and 
Additional  file  1].  The  samples  were  analyzed  on  a 
FACSCalibur flow cytometer (BD Bioscience, San Jose, CA, 
USA). Some cells were used for immunoblot analysis and 
immunofluorescent staining.
Colony forming units-fibroblastic (CFU-F) assay
CFU-F  assay  was  performed  according  to  a  previous 
study [27, and Additional file 1].
Cell proliferation assay
The proliferation of each MSC population was performed 
by  bromodeoxyuridine  (BrdU)  incorporation  assay  as 
previously described [21, 27 and Additional file 1].
Telomerase activity assay
Telomerase  activity  was  evaluated  by  telomeric  repeat 
amplification  protocol  (TRAP)  assay  using  real-time 
polymerase chain reaction (PCR) [28, and Additional file 1].
In vitro osteogenic induction assay
Osteogenic differentiation assays of SHED and BMMSCs 
were performed according to previous publications [21, 
28].  Osteogenic  markers  and  mineralized  nodule 
formation were assessed as described previously [21, 28 
and Additional file 1].
Adipogenic induction assay in vitro
Adipogenic assay in vitro of each stem cell population was 
performed  as  described  previously  [21,  28,  and 
Additional file 1].
In vivo osteogenic differentiation
Xenogeneic transplantation was performed using immuno-
compromised mice as described [21, 25, 26]. Each MSC 
population was subcutaneously transplanted into beige 
nude/nude Xid (III) mice using hydroxyapatite tricalcium 
phosphate  (HA/TCP)  as  a  carrier.  Eight  weeks  post-
transplantation,  the  transplants  were  harvested  for 
histological analysis. Detail methods were described in 
the Additional file 1.
Immunoblot analysis
Ten µg total protein was loaded and analyzed by immuno-
blotting as previously described [21, 28, and Additional 
file 1].
Co-culture of human PBMNCs or T lymphocytes with SHED 
or BMMSCs
PBMNCs  or  T  cells  were  co-cultured  with  or  without 
SHED or BMMSCs under several culture conditions as 
described  in  Additional  file  1.  Cell  death  analysis  and 
induction  of  Tregs  and  Th17  cells  were  described  in 
Additional file 1.
Xenogeneic SHED or human BMMSCs into MRL/lpr mice
Under  general  anesthesia,  SHED  or  BMMSCs  (1x105 
cells/10g body weight in 100 µl PBS) were infused into 
MRL/lpr mice via tail vein at 16 weeks (n = 3) according 
to  previous  study  [17].  MRL/lpr  mice  (16-week-old) 
received  physiological  saline  (n  =  3)  were  used  as 
experimentally control mice. All mice were sacrificed at 
20 weeks of age, and from them were collected peripheral 
blood, kidney, and long bones (femur and tibiae).
FCM analysis of Treg and Th17 cells
Flow cytometric staining and analysis were performed as 
previously reported [29, and Additional file 1].
Measurement of biomarkers in culture supernatant, blood 
serum and urine
Several biomarkers, including anti-dsDNA antibody and 
anti-nuclear antibody ANA, complement 3 (C3), inter-
leukin 6 (IL6), IL10, IL17, soluble receptor activator for 
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telopeptides of type I collagen (CTX), creatinine, urine 
protein in biofluid samples (peripheral blood serum and 
urine) were measured by enzyme linked immunosorbent 
assay (ELISA) [17, and Additional file 1].
Histological analysis of kidney and bone
Kidneys and long bones (femurs) harvested from mice 
were fixed and processed to make paraffin sections. The 
sections were used for further experiments [Additional 
file 1].
Histometry
Histomorphometric analysis was quantified as described 
previously  [25].  Detailed  methods  were  described  in 
Additional file 1.
Statistics
All  data  are  expressed  as  the  mean  ±  SD  of,  at  least, 
triplicate  determinations.  Statistical  difference  between 
the values was examined by Student’s t-test. The P values 
less than 0.05 were considered significant.
Antibodies and primer
All primary antibodies used in this study were described 
in Additional file 1 and listed on Table S1 in Additional 
file  1.  All  primer  pairs  were  listed  in  Table  S2  in 
Additional file 1
Results
SHED possess mesenchymal stem cell properties
Although  SHED  are  capable  of  differentiating  into  a 
variety  of  cell  types  [21],  their  detailed  mesenchymal 
stem cell properties remain to be elucidated. Herein, we 
used flow cytometry, immunoblot analysis, and immuno-
cytostaining analysis to demonstrate that SHED at passage 
3  expressed  many  mesenchymal  surface  markers, 
including  STRO-1,  SSEA4,  CD73,  CD105,  CD146,  and 
CD166 but were negative for CD34 and CD45 (Figures 1A-
1C).  In  comparison  to  BMMSCs,  SHED  expressed 
significantly  higher  levels  of  STRO-1  and  CD146,  and 
lower  levels  of  CD105  (Figure  1A).  Additionally,  SHED 
showed  significantly  high  numbers  of  single  colony 
clusters (colony-forming units-fibroblastic; CFU-F) and an 
elevated  cell  proliferation  rate  compared  to  BMMSCs 
(Figures 1D and 1E). This elevated proliferative capacity 
may  be  associated  with  the  significantly  increased  telo-
merase activity in SHED (Figure 1F).
To  compare  osteogenic  differentiation  of  SHED  with 
BMMSCs,  multiple  colony-derived  SHED  at  passage  3 
were supplemented with L-ascorbate-2-phosphate, dexa-
metha  sone,  and  inorganic  phosphate  to  induce 
mineraliza  tion in vitro as described previously [21]. After 
one week of induction, SHED were similar to BMMSCs, 
showing  significantly  increased  alkaline  phosphatase 
(ALP)  activity  (Figure  2A)  and  the  number  of  ALP-
positive cells by flow cytometric analysis (Figure 2B), and 
expression  of  elevated  levels  of  ALP,  Runt  related 
transcription factor 2 (Runx2), dentin sialoprotein (DSP), 
and  osteocalcin  (OCN)  by  immunoblot  analysis 
(Figure 2C). Alizarin Red-positive nodule formation in 
SHED  and  BMSMC  cultures  was  notified  after  four 
weeks of osteogenic induction, indicating calcium accu-
mu  lation in vitro (Figures 2D and 2E). However, SHED 
suffered remarkable impairment of adipogenic differen-
tiation, as shown by decreased numbers of lipid-specific 
Oil  red  O-positive  cells  and  reduced  expression  of 
adipocyte-specific  molecules,  peroxisome  proliferator-
activated  receptor  g2  (PPARg2)  and  lipoprotein  lipase 
(LPL) when compared to BMMSCs (Figures 2F-2H). To 
validate  the  capacity  of  forming  mineralized  tissue  in 
vivo  by  SHED,  ex  vivo  expanded-SHED  were 
transplanted  into  immunocompromised  mice  with 
hydroxyapatite/tri  calcium  phosphate  (HA/TCP)  as  a 
carrier. SHED formed a similar amount of mineralized 
tissue and a reduced amount of hematopoietic marrow 
components  when  compared  to  BMMSC  transplants 
(Figures  2I-2K).  Next,  we  confirmed  that  SHED  were 
similar to BMMSCs in activation of multiple signaling 
pathways, including TGFβ, ERK, Akt, Wnt, and PDGF 
(Figures 2L-2P).
Interplays between SHED and T-lymphocytes
In order to compare the immunomodulatory capacity of 
SHED with BMMSCs, anti-CD3/CD28 antibodies with 
TGFβ/IL-6  were  added  to  the  co-cultures  of  SHED  or 
BMMSCs with naïve T cells, which were purified from 
human  PBMNCs,  levels  of  IL17+IFNg-  Th17  cells  and 
IL17 were significantly reduced in SHED and BMMSC 
groups compared to the naïve T cell group (Figure 3A). It 
appeared  that  SHED  showed  a  significant  inhibiting 
effect  in  reducing  IL17  levels  when  compared  to 
BMMSCs (Figure 3B). Our previous report indicated that 
activated T cells induce apoptosis of BMMSCs through 
the Fas/FasL pathway [28]. To determine whether activated 
T  cells  also  directly  impinge  on  SHED,  as  occurs  in 
BMMSCs, SHED were co-cultured with human PBMNCs 
activated  by  anti-CD3  specific  antibody  treatment.  We 
found that the activated PBMNCs were able to induce 
part of SHED death in the co-culture system (Figure 3C). 
When  SHED  were  separated  from  PBMNCs  using  a 
Transwell  co-culture  system  or  treated  using  anti-FasL 
neutralizing antibody, SHED failed to show the cell death 
(Figure 3C), suggesting that direct cell-cell contact and 
the  Fas/FasL  pathway  are  required  for  inducing  SHED 
death by activated splenocytes. Next, we confirmed that 
SHED express Fas by immunoblot analysis (Figure 3D). 
Terminal  deoxynucleotidyl  transferase-mediated 
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used  to  confirm  that  the  SHED  death  was  due  to  cell 
apoptosis (Figure 3E).
SHED transplantation improves SLE phenotypes in 
MRL/lpr mice
Our  previous  study  showed  that  systemic  infusion  of 
BMMSCs offers appropriate treatment for SLE disorders 
in human patients and SLE-like MRL/lpr mice [17]. Here 
we selected SLE-like mice at 16 weeks of age to infuse 
SHED  for  treating  SLE  disorders  using  BMMSCs  as  a 
control (Figure 4A). It is known that autoantibodies play 
a crucial role in SLE patients. Our previous study showed 
a  remarkable  increase  in  the  levels  of  autoantibodies 
including anti-double strand DNA (dsDNA) IgG and IgM 
antibodies, and anti-nuclear antibody (ANA) in the peri-
pheral blood [17]. As seen in BMMSC trans  plan  tation, 
SHED transplantation resulted in a significant reduction 
in serum levels of anti-dsDNA IgG and IgM, and ANA 
antibodies (Figures 4B-4D).
Histological  analysis  with  hematoxylin  and  eosin, 
trichrome, and periodic acid-Schiff staining revealed that 
Figure 1. Characterization of SHED in comparison to BMMSCs. (A) Flow cytometric analysis of cultured SHED at passage 3 revealed expression 
of STRO-1 (12.06%), CD146 (48.39%), SSEA4 (85.40%), CD73 (91.93%), CD105 (6.77%), CD166 (63.65%), but was negative for surface molecules CD34 
and CD45. SHED express high levels of STRO-1 and CD146 (n = 5; P <0.05) and low level of CD105 (n = 5; P <0.01) compared to expression levels of 
STRO-1 (8.36%), CD146 (31.19%), and CD105 (13.27%) in BMMSCs. These signals are shown as the red area. Solid lines indicate signals for isotype 
matched control antibodies. M1 window show the positive expression defined as the level of fluorescence greater than 99% of the corresponding 
isoytpe-matched control antibodies. Representative histograms are shown among five donors. (B) Immunoblot analysis confirmed expression of 
CD73, CD105 and CD166 in SHED and BMMSCs. Representative images of n = 5 donors are presented as results. (C) Immunofluoresence confirmed 
that SHED express STRO-1, CD146, and SSEA4 along with negative for CD34 and CD45. Red fluorescence indicates the expression of cell surface 
markers. Blue cell nuclei were stained by DAPI. Images were representative data of independent experiment (n = 5) with consistent results 
(Bar = 50µm). (D) SHED were able to form significantly high numbers of single colonies than BMMSCs when 1x 106 cells were plated at a low density 
(*P <0.05) and cultured for 10 days. (E) The proliferation rates of SHED and BMMSCs were assessed by co-culture with BrdU for 18 hours. The number 
of BrdU-positive cells was presented as a percentage of the total number of cells counted from five replicate cultures. SHED showed a significantly 
higher proliferation rate in comparison to BMMSCs (**P <0.01). (F) SHED showed a high activity of telomerase compared to BMMSCs assessed by 
real time PCR. HEK293T cells (239T) were used as a positive control and heat inactivated 293T (H.I.) cells were used as a negative control. The activity 
was indicated by a PCR cycle threshold and averaged from three replicated cultures (***P <0.001).
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transplantation  in  recovery  of  SLE-associated  renal 
disorders,  such  as  nephritis  with  glomerular  basal 
membrane  disorder  and  messangial  proliferation  in 
MRL/lpr mice (Figure 4E). ELISA data showed that SHED 
and BMMSC transplantation was able to reduce the urine 
C3 level and elevate the serum C3 level (Figure 4F). Also, 
SHED transplantation significantly reduced urine protein 
levels compared to BMMSC transplantation (Figure 4G). 
Moreover,  SHED  and  BMMSC  transplantation  signifi-
cantly  elevated  creatinine  levels  in  urine  and  reduced 
creatinine levels in serum (Figure 4H). This experimental 
evidence  indicated  that  SHED  transplantation  is  an 
effective approach for treating SLE disorders.
Figure 2. Mesenchymal stem cell properties of SHED. (A-E) SHED showed a similar osteogenic differentiation potential to BMMSCs. After one 
week culture induction under osteogenic conditions, ALP activity and numbers of ALP positive cells in SHED and BMMSCs were significantly higher 
than that of the control SHED and BMMSCs, respectively, by ALP staining (Representative of n = 5) (A) and flow cytometric analysis (Representative 
of n = 3) (B). Meanwhile, immunoblot analysis showed that the osteogenic induction elevates expression levels of ALP, Runx2, DSP, and OCN in 
SHED and BMMSCs (C) (***P <0.001, n = 5). β-actin was used as an internal control. After four weeks culture induction in osteogenic medium, SHED 
showed increased capacity of forming mineralized nodules as assessed by alizarin red staining (Representative of n = 5). (D). Alizarin red-positive 
area corresponding to total area was averaged from five independent groups (E). (F-H) SHED showed reduced potential of differentiating into 
adipocytes compared to BMMSCs. Three weeks post adipogenic induction, lipid accumulation in SHED was less than that in BMMSCs by Oil-red O 
staining (Representative of n = 5). (F). Number of oil-red O-positive (Oil-Red-O+) cells was calculated as a percentage to total cells and averaged 
from five independent cultures (G) (*P <0.05). Immunoblot assay indicated that SHED expressed lower levels of adipocyte-specific molecules LPL 
and PPARγ than BMMSCs at three weeks post adipogenic culture (H). Three independent assays showed the similar results. (I-K) SHED were capable 
of forming mineralized tissue when transplanted subcutaneously into immunocompromised mice using HA/TCP as a carrier (Representative of n 
= 3). (I). It appeared that SHED form similar amounts of mineralized tissue as seen in a BMMSC transplant (Representative of n = 3) (I, J), but they 
generated significantly less bone marrow elements than BMMSCs (K). Newly formed mineralized tissue and bone marrow areas were calculated as 
a percentage of the total area and averaged from three independent transplant assays (***P <0.001). B = bone, BM = bone marrow, C =: connective 
tissue, H =: hydroxyapatite and tricalcium carrier. (L-P) SHED and BMMSCs express multiple signaling pathways during culture expansion at passage 
3. SHED and BMMSCs expressed TGFβ receptor I and II, Smad 2 and phosphorylated Smad 2 (L); P38, phosphorylated P38, ERK, and phosphorylated 
ERK (M); Akt and phosphorylated Akt (N); N-cadherin and β-catenin (O); PDGF receptor and Ang-1 (P). Representative image of n = 5.
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Tregs prevent pathogenic autoimmunity by suppressing 
proliferation  and  production  of  pro-inflammatory 
cytokines  in  effector  immune  cells,  such  as  helper  T-
lymphocytes  [30].  In  contrast,  Th17  cells  that  produce 
IL17  are  inflammatory  cells  responsible  for  the  patho-
genesis of autoimmune diseases [31] and bone destruc-
tion  [32].  Our  previous  study  suggested  that  BMMSC 
transplantation  affects  the  immune  balance  between 
Tregs and Th17 cells in SLE-like disorders [17]. Here we 
found that SHED transplantation showed more signifi-
cant effect in up-regulating the ratio of Treg and Th17 
cells in comparison to BMMSC transplantation in MRL/
lpr mice (Figures 5A-5C). Both SHED and BMMSC trans-
plantations showed no significant changes in the level of 
IL10  and  IL6  in  MRL/lpr  mice  (Figures  5D  and  5E); 
however,  SHED  transplantation  provided  a  remarkable 
reduction of TH17 cells and IL17 level in MRL/lpr mice 
when compared to BMMSC transplantation (Figures 5C 
and 5F).
Our  previous  study  suggested  that  BMMSC  trans-
plantation-mediated  therapy  in  SLE-like  mice  may 
associate with the reconstructing trabecular bone [17]. 
Here we found SHED were also capable of reconstructing 
trabecular bone in MRL/lpr mice (Figure 6A). In contrast 
to  BMMSC/osteoblast  lineage,  osteoclasts  play  a 
significant role in the maintenance of bone homeostasis 
by  the  bone  resorption  function.  We  compared  SHED 
transplantation with BMMSC transplantation in inhibit-
ing osteoclast activity in MRL/lpr mice and found that 
both  SHED  and  BMMSC  transplantation  were  able  to 
reduce the number of tartrate-resistant acid phosphatase 
(TRAP)-positive osteoclasts in the distal femur epiphysis 
of MRL/lpr mice (Figure 6B), serum levels of runt-related 
NF-kB  ligand  (RANKL),  a  critical  factor  for 
osteoclastogenesis  (Figure  6C),  and  bone  resorption 
marker C-terminal telopeptides of type I collagen (CTX;) 
as compared to untreated MRL/lpr mice (Figure 6D).
Discussion
BMMSCs have been successfully utilized to treat a variety 
of  human  diseases,  such  as  bone  fracture  [33],  severe 
aplastic  anemia  [34],  acute  GVHD  [13],  and  SLE  [17]. 
SLE is a common and potentially fatal immune disease in 
Figure 3. SHED interplay with T-lymphocytes. (A, B) Under the anti-CD3 and CD28 antibody along with TGFβ1 and IL-2 stimulation, SHED 
showed a significant effect in reducing Th17 cell levels as seen in BMMSCs (A), however, SHED exhibited a significant capacity of inhibiting 
IL17 levels than BMMSCs (B) (n = 3, *P <0.05,***P <0.001). (C) PBMNCs activated by anti-CD3 antibody (@CD3Ab, 1 µg/ml) were capable of 
inducing significant SHED and BMMSC death as shown by toulidin blue staining. When cells were cultured in an indirect co-culture system using 
Transwell,activated slpenocytes they failed to induce SHED and BMMSC death. Neutralization with anti-FasL antibody (@FasLAb, 1 µg/ml) blocked 
PBMNC-induced SHED and BMMSC death. Representative of n = 3. (D) SHED express a higher level of Fas in comparison to that in BMMSCs by 
immunoblotting. Three independent experiments showed similar results. Representative of n = 3. (E) SHED death caused by active PBMNCs is 
through an apoptotic pathway according to the TUNEL staining. The SHED death rate was similar to BMMSCs. The percentage of TUNEL-positive 
(TUNEL+) nuclei was indicated to the total number of MSCs and averaged from five replicated cultures (***P <0.005).
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Page 6 of 10which autoantibodies damage multiple organs, including 
the  kidneys,  cardiovascular  system,  nervous  system, 
joints, and skin [35]. The pathology of SLE involves the 
destruction of targeted organ tissues and accumulation of 
auto-reactive  lymphocytes  and  immune  complexes. 
Although  intensity  and  organ  involvement  vary 
significantly among SLE patients, abnormalities of T and 
B  lymphocytes  are  universal  [35-37].  Moreover,  SLE 
provokes  multifaceted  immune  modulation,  including 
both deficiency and hyperactivity of the immune system. 
An understanding of the underlying pathology is crucial 
to  developing  optimal  therapies  for  the  restoration  of 
immune homeostasis without compromising the protec-
tive immune responses to pathogens [38]. MRL/lpr mice 
were generated by the insertion of the early transposable 
element  ETn  in  the  Fas  gene,  which  causes  a  striking 
reduction  in  Fas  mRNA  expression  and  is  associated 
clinically  with  marked  acceleration  of  the  lupus-like 
disease [39]. Levels of circulating immune complexes rise 
enormously from about three months of age in MRL-lpr/
lpr but not in MRL mice. In this study, we used MRL/lpr 
mice as a SLE mouse model to indicate that SHED are an 
appropriate  population  of  postnatal  stem  cells  for  SLE 
treatment as seen in BMMSC-mediated therapy.
SHED are derived from a very accessible tissue resource 
and  capable  of  providing  enough  cells  for  potential 
clinical  application  via  high  proliferation  rate  and 
expression  of  telomerase  [21].  The  reason  that  SHED 
transplantation  showed  optimal  therapeutic  effect  may 
be associated with the fact that SHED showed superior 
immunomodulatory  effects  compared  to  BMMSCs  in 
terms of recovering Tregs/Th17 ratio and reducing Th17 
Figure 4. SHED transplantation reduced levels of autoantibodies and improved renal function in MRL/lpr mice. Figure 4A shows the 
scheme of SHED and BMMSC transplantation procedures. (B-D) ELISA quantified that levels of anti dsDNA IgG (B), IgM (C) and nuclear (D) 
antibodies (ANA) (mean ± SD) were significantly reduced in the peripheral blood of SHED and BMMSC treated MRL/lpr mice (n = 6) when 
compared to un-treated MRL/lpr mice c (n = 6) (***P <0.001). It appeared that SHED transplantation resulted in a more significant reduction in anti 
IgG when compared to BMMSC transplantation (B). (E) MRL/lpr mice showed renal disorders such as nephritis with glomerular basal membrane 
disorder and mesangium cell over-growth. SHED and BMSSC transplantation resulted in a reduced basal membrane disorder and mesangium 
cell over-growth in glomerular (G) (upper panels, H&E staining; middle panels, trichrome staining; lower panels, periodic acid-schiff staining). 
Representative images of un-treated, SHED and BMMSC MRL/lpr (n = 6). (F) ELISA analysis showed that SHED transplantation has the same effect 
as seen in BMMSC transplantation in significantly reducing C3 level in urine and elevating C3 level in serum (n = 6, *P <0.05, **P <0.01). (G) SHED 
transplantation significantly reduced urine protein levels (mean ± SD) compared to BMMSC transplanted MRL/lpr mice (n = 6). (***P <0.001). 
(H) Markedly increased urine creatinine and reduced serum creatinine were observed in SHED and BMMSC transplanted MRL/lpr mice (n = 6) 
compared to un-treated MRL/lpr mice (n = 6, ***P <0.001, **P <0.01).
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Page 7 of 10Figure 5. The ratio of Tregs and Th17 cells may contribute to SHED mediated treatment in MRL/lpr mice. (A-C) Flow cytometric analysis 
showed that the number of CD25+Foxp3+ Tregs in CD4+ T lymphocytes of MRL/lpr spleen was not significantly changed in SHED and BMMSC 
transplantation (A). In contrast, SHED and BMMSC transplantation were capable of significantly reduced levels of CD4+IL17+ cells in spleen as 
compared to un-treated MRL/lpr mice (B). SHED transplantation significantly increased the ratio of Tregs and Th17 cells when compared to BMMSC 
transplantation group (C) (***P <0.001, **P <0.01, *P <0.05). Results were shown as mean ± SD from un-treated, SHED and BMMSC MRL/lpr (n = 6). 
(D-F) Although SHED and BMMSC transplantations failed to alter IL10 (D) and IL6 (E) levels in serum of MRL/lpr mice, IL17 levels were significantly 
down-regulated in SHED and BMMSC transplanted group compared to un-treated MRL/lpr mice (F). Results were shown as means ± SD from un-
treated, SHED and BMMSC MRL/lpr (n = 6).
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Figure 6. SHED transplantation reconstructed trabecular bone and inhibited osteoclast activity. (A) SHED transplantation showed the same 
effect in regenerating trabecular bone as seen in BMMSC transplanted MRL/lpr mice (n = 6) (**P <0.01). (B) TRAP staining showed that the number 
of TRAP positive osteoclasts was significantly reduced in SHED and BMMSC transplanted mice (n = 6, *P <0.05). (C, D) ELISA revealed that SHED and 
BMMSC transplantations were capable of significantly reducing the levels (mean ± SD) of soluble RANKL (sRANKL) (C) and C-terminal telopeptides 
of type I collagen (CTX) (D) in serum of MRL/lpr mice (n = 6) (*P <0.05, **P <0.01).
!
"!
#!
T
r
a
b
e
c
u
l
a
r
 
b
o
n
e
a
r
e
a
 
(
%
/
c
i
r
c
l
e
 
a
r
e
a
)
MRL/lpr
MRL/lpr
+BMMSC
MRL/lpr
+SHED
**
**
!
"!
#!
MRL/lpr
MRL/lpr
+BMMSC
MRL/lpr
+SHED
T
R
A
P
 
p
o
s
i
t
i
v
e
 
c
e
l
l
n
u
m
b
e
r
 
(
/
b
o
n
e
 
a
r
e
a
)
* *
!
"
#
*
*
MRL/lpr
MRL/lpr
+BMMSC
MRL/lpr
+SHED
A B C D
!
"#
#!
**
**
MRL/lpr
MRL/lpr
+BMMSC
MRL/lpr
+SHED
s
R
A
N
K
L
 
l
e
v
e
l
 
i
n
s
e
r
u
m
 
(
n
g
/
m
L
)
C
T
X
 
l
e
v
e
l
 
i
n
s
e
r
u
m
 
(
n
g
/
m
L
)
Figure 6
Yamaza et al. Stem Cell Research & Therapy 2010, 1:5 
http://stemcellres.com/content/1/1/5
Page 8 of 10cell  levels  in  peripheral  blood.  In  addition,  SHED 
transplantation,  as  seen  in  BMMSC  transplantation,  is 
capable  of  recovering  trabecular  bone  and  inhibiting 
osteoclast activity, suggesting that SHED transplantation, 
as  seen  in  BMMSC  transplantation,  could  lead  the 
reconstruction  of  osteoblastic  niche  to  improve  SLE 
disorders in SLE patients and a SLE-like murine model 
[17]. Therefore, SHED may be an appropriate stem cell 
resource  for  treating  immune  disorders  via  improved 
immuno  modulatory  properties.  Systemic  infusion  of 
SHED fails to show a significant promoting Treg level in 
SLE-like mice as seen in an in vitro co-culture system, 
which may be associated with a complex in vivo condition 
that  hardly  compares  to  a  simple  co-culture  system. 
However, SHED infusion resulted in a significantly up-
regulated level of the ratio between Tregs and Th17 cells. 
This is an important index indicating immunomodulatory 
function  of  SHED  due  to  the  fact  that  Tregs  prevent 
autoimmunity and Th17 cells promote autoimmunity and 
inflammation [40].
The transition from deciduous teeth to adult perma-
nent teeth is a unique and dynamic process in which the 
development  and  eruption  of  permanent  teeth  is 
coordinated with the resorption of deciduous teeth. We 
found that exfoliated deciduous tooth crowns contain a 
remnant of living pulp comprised of a normal dental pulp 
structure, including connective tissue, blood vessels, and 
odontoblasts [21]. We demonstrated that these remnants 
of  pulp  tissues  in  exfoliated  deciduous  teeth  contain 
SHED [21]. These studies provide the first evi  dence that a 
naturally occurring exfoliated organ contains stem cells 
with the ability to form multiple phenotypes, and that 
these stem cells may offer a unique stem cell resource for 
potential  clinical  applications.  SHED  are  very  easily 
acquired from exfoliated teeth and can be expanded ex 
vivo  to  achieve  sufficient  numbers  of  cells  for  tissue 
regeneration such as repairing parietal defects [24].
Conclusions
SHED possess similar stem cell properties as those seen 
in  BMMSCs,  including  osteo/odontogenic  and  adipo-
genic differentiation in vitro, forming mineralized tissue 
in vivo, and expression of extensive mesenchymal stem 
cell markers. Moreover, systemic SHED trans  plantation 
is  capable  of  offering  similar,  if  not  better,  therapeutic 
effect  on  SLE  murine  model,  suggesting  that  easily 
accessed  SHED  may  be  a  feasible  stem  cell  source  for 
stem cell therapies.
Abbreviations
ALP = alkaline phosphatase; BMMSC = bone marrow mesenchymal stem cells; 
BrdU = bromodeoxyuridine; C3 = complement 3; CFU = colony forming units-
fibroblastic; CTX = C-terminal telopeptides of type I collagen; DSP = dentin 
sialoprotein; FCM = flow cytometry; HA/TCP = hydroxyapatite tricalcium 
phosphate; IL= interleukin; LPL = lipoprotein lipase; OCN = osteocalcin; 
PBMNCs = peripheral blood mononuclear cells; PCR = polymerase chain 
reaction; PPARγ2 = peroxisome proliferator-activated receptor γ2; Runx2 = 
Runt related transcription factor 2; Th17 = T helper 17; TRAP = telomeric 
repeat amplification protocol; Tregs = regulatory T cells; TUNEL = Terminal 
deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling; SHED = 
Stem cells from human exfoliated deciduous teeth; SLE = systemic lupus 
erythematosus; sRANKL = soluble receptor activator for nuclear factor κB 
ligand.
Competing Interests
The authors declare that they have no competing interests.
Authors’ contributions
TY and KA collected and assembled data, and worked on data analysis and 
interpretation. CC collected and assembled data. YL worked on data analysis 
and interpretation. YS, SG and SW worked on conception and design, and SS 
worked on conception and design, data analysis and interpretation and wrote 
the manuscript.
Acknowledgements
This work was supported by grants from the National Institute of Dental and 
Craniofacial Research, National Institutes of Health, Department of Health and 
Human Services (R01DE017449 to S.S. and ARRA R01DE019413 to S.S. and Y.S.).
Author details
1Center for Craniofacial Molecular Biology, University of Southern California 
School of Dentistry, 2250 Alcazar Street, CSA 103, Los Angeles, CA 90033, 
USA. 2Department of Oral Anatomy and Cell Biology, Kyushu University 
Graduate School of Dental Science, Fukuoka 812-8582, Japan. 3Department 
of Molecular Genetics, Microbiology and Immunology, Robert Wood Johnson 
Medical School, University of Medicine and Dentistry of New Jersey, 661 Hoes 
Lane, Piscataway, NJ 08854, USA. 4Mesenchymal Stem Cell Group, Division of 
Haematology, Institute of Medical and Veterinary Science/Hanson Institute/
CSCR, University of Adelaide, Frome Rd, Adelaide, SA 5000, Australia. 5Salivary 
Gland Disease Center and the Molecular Laboratory for Gene Therapy & Tooth 
Regeneration, Capital Medical University School of Stomatology, Tian Tan Xi Li 
No.4, Beijing 100050, China.
Received: 18 Jul 2009   Accepted: 15 Mar 2010   Published: 15 Mar 2010
References
1.  Prockop DJ: Marrow stromal cells as stem cells for nonhematopoietic 
tissues. Science 1997, 276:71-74.
2.  Bianco P, Riminucci M, Gronthos S, Robey PG: Bone marrow stromal stem 
cells: nature, biology, and potential applications. Stem Cells 2001, 
19:180-192.
3.  Friedenstein AJ, Chailakhyan RK, Latsinik NV, Panasyuk AF, Keiliss-Borok IV: 
Stromal cells responsible for transferring the microenvironment of the 
hemopoietic tissues. Cloning in vitro and retransplantation in vivo. 
Transplantation 1974, 17:331-340.
4.  Owen M, Friedenstein AJ: Stromal stem cells: marrow-derived osteogenic 
precursors. Ciba Found Symp 1988, 136:42-60.
5.  Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, 
Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential of 
adult human mesenchymal stem cells. Science 1999, 284:143-147.
6.  Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W, 
Devine S, Ucker D, Deans R, Moseley A, Hoffman R: Mesenchymal stem cells 
suppress lymphocyte proliferation in vitro and prolong skin graft survival 
in vivo. Exp Hematol 2002, 30:42-48.
7.  Uccelli A, Pistoia V, Moretta L: Mesenchymal stem cells: A new strategy for 
immunosuppression? Trends Immunol 2007, 28:219–226.
8.  Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, Risso M, 
Gualandi F, Mancardi GL, Pistoia V, Uccelli A: Human mesenchymal stem 
cells modulate B-cell functions. Blood 2006, 107:367–372.
9.  Rasmusson I, Le Blanc K, Sundberg B, Ringdén O: Mesenchymal stem cells 
Additional file 1. Supplementary Materials and methods and 
2 supplementary tables. A PDF file containing supplementary 
Materials and methods and 2 supplementary tables: Table S1 displays 
information on antibodies; and Table S2, lists PCR primers.
Yamaza et al. Stem Cell Research & Therapy 2010, 1:5 
http://stemcellres.com/content/1/1/5
Page 9 of 10stimulate antibody secretion in human B cells. Scand. J Immunol 2007, 
65:336–343.
10.  Ramasamy R, Fazekasova H, Lam EW, Soeiro I, Lombardi G, Dazzi F: 
Mesenchymal stem cells inhibit dendritic cell differentiation and function 
by preventing entry into the cell cycle. Transplantation 2007, 83:71–76.
11.  Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L: 
Mesenchymalstemcell-natural killer cell interactions: Evidence that 
activated NK cells are capable of killing MSCs, whereas MSCs can inhibit 
IL-2-induced NK-cell proliferation. Blood 2006, 107:1484–1490.
12.  Aggarwal S, Pittenger MF: Human mesenchymal stem cells modulate 
allogeneic immune cell responses. Blood 2005, 105:1815-1822.
13.  Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg 
B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe W, 
Ringdén O; Developmental Committee of the European Group for Blood 
and Marrow Transplantation: Treatment of severe acute graft-versus-host 
disease with third party haploidentical mesenchymal stem cells. Lancet 
2004, 363:1439-1441.
14.  Chen X, Armstrong MA, Li G: Mesenchymal stem cells in immunoregulation. 
Immunol Cell Biol 2006, 84:413-421.
15.  Koç ON, Gerson SL, Cooper BW, Laughlin M, Meyerson H, Kutteh L, Fox RM, 
Szekely EM, Tainer N, Lazarus HM: Rapid hematopoietic recovery after 
coinfusion of autologous-blood stem cells and culture-expanded marrow 
mesenchymal stem cells in advanced breast cancer patients receiving 
high-dose chemotherapy. J Clin Oncol 2000, 18:307–316.
16.  Noort WA, Kruisselbrink AB, in’t Anker PS, Kruger M, van Bezooijen RL, de Paus 
RA, Heemskerk MH, Löwik CW, Falkenburg JH, Willemze R, Fibbe WE: 
Mesenchymal stem cells promote engraftment of human umbilical cord 
blood-derived CD34 cells in NOD/SCID mice. Exp Hematol 2002, 
30:870–878.
17.  Sun L, Akiyama K, Zhang H, Yamaza T, Hou Y, Zhao S, Xu T, Le A, Shi S: 
Mesenchymal stem cell transplantation reverses multi-organ dysfunction 
in systemic lupus erythematosus mice and humans. Stem Cells 2009, 
27:1421-1432.
18.  Banas A, Teratani T, Yamamoto Y, Tokuhara M, Takeshita F, Osaki M, Kawamata 
M, Kato T, Okochi H, Ochiya T: IFATS collection: in vivo therapeutic potential 
of human adipose tissue mesenchymal stem cells after transplantation 
into mice with liver injury. Stem Cells 2008, 26:2705-2712. 
19.  Cho KS, Park HK, Park HY, Jung JS, Jeon SG, Kim YK, Roh HJ:  IFATS collection: 
Immunomodulatory effects of adipose tissue-derived stem cells in an 
allergic rhinitis mouse model. Stem Cells 2009, 27:259-265.
20.  Wada N, Menicanin D, Shi S, Bartold PM, Gronthos S: Immunomodulatory 
properties of human periodontal ligament stem cells. J Cell Physiol. 2009, 
219:667-676.
21.  Miura M, Gronthos S, Zhao M, Lu B, Fisher LW, Robey PG, Shi S: SHED: Stem 
cells from human exfoliated deciduous teeth. Proc Natl Acad Sci U S A 2003, 
100:5807-5812.
22.  Laino G, Graziano A, d’Aquino R, Pirozzi G, Lanza V, Valiante S, De Rosa A, Naro 
F, Vivarelli E, Papaccio G: An approachable human adult stem cell source for 
hard-tissue engineering. J Cell Physiol. 2006, 206:693-701.
23.  Zheng Y, Liu Y, Zhang CM, Zhang HY, Li WH, Shi S, Le AD, Wang SL: Stem cells 
from deciduous tooth repair mandibular defect in swine. J Dent Res 2009, 
88:249-254.
24.  Seo BM, Sonoyama W, Coppe C, Kikuiri T, Akiyama K, Lee JS, Shi S: SHED 
repair critical-size calvarial defects in immunocompromised mice. Oral 
Diseases 2008, 14:428-434.
25.  Yamaza T, Miura Y, Akiyama K, Bi Y, Sonoyama W, Gronthos S, Chen W, Le A, Shi 
S: Mesenchymal Stem Cell-Mediated Ectopic Hematopoiesis Alleviates 
Aging-Related Phenotype in Immunocompromised Mice. Blood 2009, 
113:2595-2604.
26.  Shi S, Gronthos S, Chen S, Reddi A, Counter CM, Robey PG, Wang CY: Bone 
formation by human postnatal bone marrow stromal stem cells is 
enhanced by telomerase expression. Nat Biotechnol 2002, 20:587-591.
27.  Gronthos S, Mankani M, Brahim J, Robey PG, Shi S: Post-natal dental pulp 
stem cells in vivo and in vitro. Proc Natl Acad Sci U S A 2000, 97:13625-13630.
28.  Yamaza T, Miura Y, Bi Y, Liu Y, Akiyama K, Sonoyama W, Patel V, Gutkind S, 
Young M, Gronthos S, Le A, Wang CY, Chen W, Shi S: Pharmacologic stem cell 
based intervention as a new approach to osteoporosis treatment in 
rodents. PLoS ONE 2008, 3:e2615
29.  Liu Y, Zheng Y, Ding G, Fang D, Zhang C, Bartold PM, Gronthos S, Shi S, Wang 
S: Periodontal ligament stem cell-mediated treatment for periodontitis in 
miniature swine. Stem Cells 2008, 26:1065–1073.
30.  La Cava A: T-regulatory cells in systemic lupus erythematosus. Lupus 2008, 
17:421-425.
31.  Garrett-Sinha LA, John S, Gaffen SL: IL-17 and the Th17 lineage in systemic 
lupus erythematosus. Curr Opin Rheumatol 2008, 20:519-525.
32.  Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, Tanaka 
S, Kodama T, Akira S, Iwakura Y, Cua DJ, Takayanagi H: Th17 functions as an 
osteoclastogenic helper T cell subset that links T cell activation and bone 
destruction. J Exp Med 2006, 203:2673-2682.
33.  El-Badri NS, Hakki A, Ferrari A, Shamekh R, Good RA: Autoimmune disease: is 
it a disorder of the microenvironment? Immunol Res 2008, 41:79-86.
34.  Cordeiro AC, Isenberg DA: Novel therapies in lupus - focus on nephritis. 
Acta Reumatol Port 2008, 33:157-169.
35.  Rahman A, Isenberg DA: Systemic lupus erythematosus. N Engl J Med 2008, 
358:929-939.
36.  Kyttaris VC, Juang YT, Tsokos GC: Immune cells and cytokines in systemic 
lupus erythematosus: an update. Curr Opin Rheumatol 2005, 17:518-522.
37.  Crispin JC, Tsokos GC: Novel molecular targets in the treatment of systemic 
lupus erythematosus.  Autoimmun Rev 2008, 7:256-261.
38.  Ramanujam M, Davidson A: Targeting of the immune system in systemic 
lupus erythematosus. Expert Rev Mol Med 2008, 10:e2. 
39.  Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K, Wiethe C, 
Winkler TH, Kalden JR, Manz RA, Voll RE: The proteasome inhibitor 
bortezomib depletes plasma cells and protects mice with lupus-like 
disease from nephritis. Nat Med 2008, 14:748-755.
40.  Mucida D, Park Y, Kim G, Turovskaya O, Scott I, Kronenberg M, Cheroutre H: 
Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic 
acid. Science 2007, 317:256-260.
doi:10.1186/scrt5
Cite this article as: Yamaza T, et al.: Immunomodulatory properties of stem 
cells from human exfoliated deciduous teeth. Stem Cell Research & Therapy 
2010, 1:5.
Yamaza et al. Stem Cell Research & Therapy 2010, 1:5 
http://stemcellres.com/content/1/1/5
Page 10 of 10